On October 9, 2019 ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, reported that its Chief Executive Officer, Ian Wilson, will present an update on ImaginaAb and progress achieved with the CD8 ImmunoPET minibody at the upcoming Innovation Showcase 2019 on Monday, October 14, 2019, at The Lundquist Institute (formerly LA BioMed), 1124 West Carson Street, Torrance, CA (Press release, ImaginAb, OCT 9, 2019, View Source [SID1234540127]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Innovation Showcase is a prestigious forum where academic institutions promote and share their startups and early-stage technologies. ImaginAb joins 24 curated bioscience companies presenting with two tracks – therapeutics and medical device/other – along with a distinguished lineup of speakers that includes Bethany Mancilla, Vice President Corporate Development, Kite Pharma, a Gilead Company; David Meyer, President and Chief Executive Officer, The Lundquist Institute; Frank Stonebanks, Founder, Managing Partner, KickFlip BioVentures; Helen Kim, Managing Director, Vida Ventures.

ImaginAb will also be attending the following events in October 2019.

2nd Annual Advances in Immuno-Oncology USA Congress
October 8-9, 2019, DoubleTree by Hilton Hotel, San Diego, CA, USA
Ian Wilson, CEO, will be chairing a Panel Discussion on ‘Technological Challenges In Clinical Studies’ on October 9 at 13.30 PDT, Room 4.
Ian will also be presenting a session on ‘Insights on Reverse Translation for Patient Stratification in Clinical Studies’ on October 9 at 16.30 PDT, Room 4.

Optimum 11th Annual Healthcare Investor Conference
October 17, 2019, Bloomberg Headquarters, 3 Queen Victoria St, London, UK
Ian Wilson, CEO, and Ivan Plavec, CBO, will be attending and hosting meetings.

For further information or to schedule a meeting, please contact:

ImaginAb
Ian Wilson
Email: [email protected]
Phone: +1 310 645 1211

Optimum Strategic Communications
Mary Clark, Supriya Mathur, Manel Mateus
Email: [email protected]
Phone: +44 20 3950 9144

On October 9, 2019, Geron Corporation ("Geron" or the "Company") reported that it entered into an office lease agreement (the "Hillsdale Lease") with Hudson Metro Center LLC (the "Landlord"), with respect to office space within the premises located at 919 East Hillsdale Boulevard, Foster City, California (the "Hillsdale Office") (Filing, 8-K, Geron, OCT 9, 2019, View Source [SID1234542251]). The purpose of the Hillsdale Lease is to replace the Company’s current leased premises at 149 Commonwealth Drive, Suite 2070, Menlo Park, California. The initial term of the Hillsdale Lease for the Hillsdale Office is 87 months, with an option by Geron to extend for an additional five years. Also, in connection with the Hillsdale Lease, Geron has provided a security deposit to the Landlord of $310,662.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Geron has not yet occupied the Hillsdale Office as it is being prepared for the Company’s use. The Hillsdale Lease term commences upon the earlier of the date of completion of construction, which is expected to occur by March 1, 2020, or the date upon which the Company first conducts business in the Hillsdale Office. Upon the commencement of the Hillsdale Lease, the aggregate minimum future lease payments for the initial lease term is approximately $4.4 million, net of a three-month rent abatement period, and subject to scheduled annual increases. In addition, the Company is responsible for paying its pro-rata share of certain building operating expenses and taxes throughout the term of the lease.

If the Hillsdale Lease does not commence on or before August 1, 2020, Geron may terminate the Hillsdale Lease without penalty and any prepaid monthly rent payments and any undrawn security deposit will be returned by the Landlord to Geron.

The foregoing description of the Hillsdale Lease is not complete and is qualified in its entirety by reference to the full text of the Hillsdale Lease, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On October 9, 2019 Horizon Therapeutics plc (Nasdaq: HZNP) reported that its third-quarter 2019 financial results will be released on Wednesday, Nov. 6, 2019 (Press release, Horizon Therapeutics, OCT 9, 2019, View Source [SID1234540128]). Following the announcement, Horizon’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast and a replay may be accessed at View Source Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the webcast will be available approximately two hours after the live webcast.

On October 9, 2019 Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, reported that it will be presenting at the inaugural MicroCap Rodeo Investor Conference in Austin, Texas on Tuesday, October 15 at 9:10 a.m. CDT (Press release, Genprex, OCT 9, 2019, View Source [SID1234540129]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be available for one-on-one investor meetings. The presentation will also be available via live webcast. Following the presentation, an archived recording will be available for later viewing.

Genprex will present at the MicroCap Rodeo Investor Conference as follows:

Date: Tuesday, October 15, 2019

Time: 9:10 a.m. CDT

Venue: Hilton Austin – Downtown, 500 East 4th Street, Austin, Texas 78701

Webcast: View Source

To learn more about the MicroCap Rodeo’s inaugural event October 15-16, 2019 in Austin, please visit microcaprodeo.com. Registration is free. The MicroCap Rodeo is focused on the best ideas concept, bringing some of the best stories to the event for two days of private meetings, presentations and after-hours networking.

On October 9, 2019 Pharm-Olam, a global midsized CRO, reported that the company’s board of directors has elected Robert Davie, Ph.D., as its new chief executive officer (Press release, Pharm-Olam International LTD, OCT 9, 2019, View Source [SID1234540130]). Pharm-Olam provides full-service clinical development solutions for oncology-hematology, infectious disease, vaccines, and rare diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Davie succeeds David Grange who has served as Pharm-Olam’s CEO since April 2017. Grange will remain a director and vice chairman of the company’s board and will continue to support the organization and its work in U.S. government-funded research, which is an expanding area of Pharm-Olam’s business.

"Rob Davie is a respected leader who has worked within the CRO industry for over 25 years. We look forward to his leadership and knowledge supporting the continued growth of Pharm-Olam," said Zev Munk. M.D., founder and chairman of the board. "We also extend our sincere thanks to David Grange for his leadership over the past two-and-a-half years, having transformed Pharm-Olam’s therapeutic focus while achieving record sales for 2018."

Davie previously held critical roles within Covance, most recently as vice president and general manager of global clinical development.

"Pharm-Olam presents a unique opportunity with an organization already positioned for continued expansion, and where I can leverage my expertise in scaling a CRO to achieve its accelerated growth strategy," Davie said.

Grange expressed his appreciation to the Pharm-Olam team and the sponsors the company serves. "I am leaving them in excellent hands," Grange said. "With Rob as its leader, Pharm-Olam will continue supporting our sponsors and helping them create a healthier world for the patients and treatments we research."